Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
about
Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation.New treatments for the motor symptoms of Parkinson's disease.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system.What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.The safety of istradefylline for the treatment of Parkinson's disease.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Promising therapeutic agents for the treatment of Parkinson's disease.Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.Non-human primate models of PD to test novel therapies.Human monocyte recognition of adenosine-based cyclic dinucleotides unveils the A2a Gαs protein-coupled receptor tonic inhibition of mitochondrially induced cell death.The effect of istradefylline for Parkinson's disease: A meta-analysis.Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.
P2860
Q34014053-5A137F33-583E-4A3C-B390-B17B666236D6Q34123200-5E0771A7-6FA7-41D4-85D8-A4082ADEA54EQ34443682-D50C89BB-9C8A-4BFA-8DB3-18834C0CAF9CQ38199744-2396B5F7-7AFF-4074-82E5-1BF8B49E9A7FQ38200930-0FF603DC-FB5D-4885-B24F-4485616099A0Q38210280-7B9E5D07-8E0C-4801-884C-3B58D00AA817Q38212033-C864FEC0-7493-43D9-A300-91422000B5ECQ38353204-3470DEF9-EAAA-48A2-8BB6-4E4DB31DCCADQ38636630-5EF2CB1A-78AF-47D5-8642-9EF2ACE640B7Q38767711-2AC82647-56F3-4057-ACCD-63DDB9DF32FFQ38947507-A97329C6-B6B5-42E8-892C-3CD69B70276FQ39229450-AA21763F-E3A4-4D23-B02D-DCC06B601E10Q41668968-8245D1E2-9641-4C1D-8F2D-5488E15DC008Q47138950-A05F36F5-9877-4250-B218-CC134D9A3F91Q53059036-6D1E9BFF-B81D-4F3C-AA48-35CD56B1AE63
P2860
Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@ast
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@en
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@nl
type
label
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@ast
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@en
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@nl
prefLabel
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@ast
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@en
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@nl
P2093
P1476
Istradefylline, an adenosine A ...... on's Disease: a meta-analysis.
@en
P2093
Haiping Wei
Hongquan Wang
Hongtao Wei
Wanqiang Chen
P356
10.1016/J.JNS.2012.08.030
P577
2012-10-22T00:00:00Z